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The interest around small-animal cardiac radionuclide imaging is growing as rodent mod-
els can be manipulated to allow the simulation of human diseases. In addition to new 
radiopharmaceuticals testing, often researchers apply well-established probes to animal 
models, to follow the evolution of the target disease. This reverse translation of standard 
radiopharmaceuticals to rodent models is complicated by technical shortcomings and 
by obvious differences between human and rodent cardiac physiology. In addition, 
radionuclide studies involving small animals are affected by several extrinsic variables, 
such as the choice of anesthetic. In this paper, we review the major cardiac features that 
can be studied with classical single-photon and positron-emitting radiopharmaceuticals, 
namely, cardiac function, perfusion and metabolism, as well as the results and pitfalls of 
small-animal radionuclide imaging techniques. In addition, we provide a concise guide 
to the understanding of the most frequently used anesthetics such as ketamine/xylazine, 
isoflurane, and pentobarbital. We address in particular their mechanisms of action and 
the potential effects on radionuclide imaging. Indeed, cardiac function, perfusion, and 
metabolism can all be significantly affected by varying anesthetics and animal handling 
conditions.
Keywords: small-animal imaging, rodents, myocardial scintigraphy, anesthesia, 18F-FdG pet, micro-pet, 
micro-speCt, cardiac imaging
introdUCtion
The use of small animals for radionuclide cardiac imaging is of increasing interest and goes essen-
tially in two opposite directions. One is the reverse translation of standard protocols from humans 
to animals, and the other is the forward development of new probes from animals to humans. The 
first exploits the unique opportunity that rodents offer for simulating the evolutions of human dis-
eases under various genetic alterations and/or pharmacological interventions, whereas the second 
represents a way of expanding the number of the physiopathological processes that can be exploited 
to produce images.
This paper is primarily aimed to be a support in the first scenario that has been outlined ear-
lier. In particular, we wanted to show that standard radionuclide tracers are applicable to cardiac 
small-animal imaging at the conditions that researchers take into account and control the potential 
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source of errors and limitations that can be encountered. We 
will first review the radionuclide techniques that are more often 
translated back to rodents, then we will give examples of the 
potential sources of variability that might make such translation 
difficult. Among these, the general characteristics of the most 
commonly used anesthetics in laboratory rodents will be shortly 
reviewed, along with their specific effects on cardiac function and 
additional metabolic changes potentially relevant to radionuclide 
cardiac studies.
peCULiarities oF rodent CardiaC 
pHenotype
Several differences in cardiac anatomy and physiology exist 
between rodents and humans, which must be considered in 
translational research and that might be exacerbated in particular 
settings of artificially altered genetics (1). Particularly relevant to 
cardiac radionuclide studies are differences in cardiac dimen-
sions, coronary anatomy, and cardiac hemodynamic. A detailed 
description of such differences is beyond the scope of this review 
as heart chambers’ volume and weight vary with age and across 
genders and strains. As a general rule of thumb, rodents have 
a heart weighting roughly three orders of magnitude less than 
that of humans, though heart-to-body weight ratio is similar. 
As far as cardiac function is concerned, heart rate (HR) is much 
faster in rodents than in humans, hence increasing the energetic 
demand. Nonetheless, stroke volume corrected for body weight 
is similar to humans, resulting in relatively much higher cardiac 
output (1). Coronary anatomy has some peculiarities as well. 
In mice, the interventricular septum is selectively supplied by a 
major septal coronary artery, while, in the absence of a circumflex 
artery similar to that of humans, both anterior and lateral walls 
of the left ventricle are perfused by the left anterior descending 
(2). As a consequence, the septum is always spared in ischemic 
models exploiting the ligation of the left anterior descending. 
Rats share the presence of a septal artery with mice; however, the 
presences of a circumflex artery and of a bigger right coronary 
artery make their pattern of perfusion closer to that of humans 
(3). Additional differences between humans and rodents pertain 
to the sympathetic cardiac activity. Previous studies on rats have 
demonstrated a higher neuronal catecholamine activity and more 
rapid turnover in rats than in humans (4).
MeasUreMent oF CardiaC FUnCtion
Very high spatial and temporal resolutions are needed to cope 
with the small size and fast movement of the rodent heart. The 
first studies of cardiac function in rodents were obtained with 
clinical cameras or dedicated small-animal SPECT machines 
mounting single pinhole collimators, which allowed a spatial 
resolution in the range of millimeters. Newer micro-SPECT/
CT cameras equipped with multi pinhole collimators offer sub-
millimetrical resolution. However, detection sensitivity of SPECT 
and SPECT/CT cameras is generally low, requiring the injection 
of high activities or long scan duration. On the other hand, the 
resolution of micro-PET/CT systems is intrinsically limited to the 
range of 1–2 mm by the positron path length in tissue and by the 
non-collinearity of positron-electron annihilation; however, due 
to the lack of collimation, detection sensitivity is in general much 
higher with PET/CT than with SPECT/CT (5–8).
speCt
Left ventricular volumes and ejection fraction (LVEF) can be esti-
mated with either gated-perfusion SPECT or gated-blood pool 
(GBP) SPECT with labeled erythrocytes. Due to the simultane-
ous visualization of both ventricular chambers, GBP allows for 
quantifying right ventricular volumes, as well. The feasibility and 
reproducibility of both perfusion and GBP SPECT was assessed 
by Vanhove and colleagues in healthy male Wistar rats using a 
clinical gamma camera equipped with a single pinhole collima-
tor and a home-made modified reconstruction algorithm (9). By 
injecting 439 ± 52 MBq 99mTc-sestamibi and 520 ± 49 MBq of 
99mTc-pertechnetate for erythrocyte labeling, respectively, these 
authors showed good image quality and interscan reproducibility 
with both techniques; however, perfusion SPECT showed better 
inter and intra-observer reproducibility of estimated parameters 
than GBP SPECT (9).
An excellent interscan reproducibility of 99mTc-tetrofosmin 
SPECT was later confirmed by Strydhorst et al. in healthy and 
infarcted male Sprague-Dawley rats by means of a dedicated 
small-animal SPECT that allowed scaling the injected activities 
down to 78 ± 15 MBq (10). Though lacking direct comparison 
with ultrasounds or magnetic resonance (MR), this paper strongly 
supports longitudinal evaluation of cardiac function by perfusion 
SPECT, especially in models of ischemic disease, in which a larger 
number of animals would be required to test a single hypothesis, 
as intersubject variability is large (10).
A micro-SPECT camera was used by Constantinesco et  al. 
for assessing left ventricular perfusion and function with 
350–450 MBq 99mTc-tetrofosmin in CD1 female mice (11). This 
study showed the feasibility of obtaining meaningful functional 
parameters, such as ventricular volumes and walls’ motion, in 
mice, with a resolution of about 1  mm. Interestingly, clinical 
available software packages (i.e., QPS and QGS, GE Healthcare) 
were used for the analysis after appropriate rescaling to smaller 
voxel size (11).
Chin and colleagues assessed left ventricular function with 
GBP SPECT in wild type C567BL/6 mice (99mTc-pertecnetate, 
444  MBq), showing GBP SPECT to be able to correctly dis-
criminate between normal and infarcted animals, identifying 
segmental anomalies in this latter group (12).
More recently, other groups have used newer small-animal 
SPECT/CT cameras for longitudinal monitoring of mouse cardiac 
function after focal external beam irradiation. Perfusion images 
with 99mTc-tetrofosmin were obtained at several time points 
(range of administered activities: 65–70  MBq) and functional 
changes were similar to that seen with ultrasounds (13, 14).
pet
18Fluorodeoxyglucose (18F-FDG) was used as a tracer in first 
gated-PET studies aiming at quantifying systolic function and left 
ventricular volumes. Generally, only dedicated small-animal PET 
cameras were used for this purpose. Croteau et al. demonstrated 
tabLe 1 | Quantification of functional parameters in small-animal cardiac radionuclide studies.
reference type/sex strain technique presence of 
infarct (y/n)
ejection fraction 
(mean) (%)
end-diastolic 
volume (mean) (µL)
end-systolic volume 
(mean) (µL)
Vanhove et al. (9) Rat/male Wistar 99mTc-Sestamibi N 74 704 182
Blood pool SPECT N 65 644 227
Strydhorst et al. (10) Rat/male Sprague-
Dawley
99mTc-Tetrofosmin N 57 470 203
Y 45 834 462
Constantinesco et al. (11) Mouse/female CD1 99mTc-Tetrofosmin N 60 50 20
Chin et al. (12) Mouse/NS C57BL/6 Blood pool SPECT N 64 49.9 18.1
Y 32 73.7 53.9
Croteau et al. (15) Rat/male Sprague-
Dawley
18F-FDG N 83.2 496 90
Y 54.6 730 353
Stegger et al. (16) Mouse/NS C57BL/6 18F-FDG N 68 72 23
Y 32 132 92
Szymanski et al. (17) Rat/male Wistar 18F-FDG N 74.9 490 120
Y 54.9 700 320
13N-NH3 N 75.3 530 140
Y 45.6 750 400
The results of ancillary feasibility studies using SPECT and PET are summarized.
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the feasibility of accurate systolic function assessment in the 
volume range of 150–1,000  µL in normal and infarcted male 
Sprague-Dawley rats imaged with camera achieving a transaxial 
resolution of 2.1 mm (injected activity 111–185 MBq 18F-FDG) 
(15). In normal animals, a good correlation (R2 = 0.89) between 
PET and ultrasonographic estimation of ventricular volumes and 
LVEF was shown, whereas ventricular volumes measured with 
ultrasound showed a greater dispersion in diseased animals, 
resulting in only fair correlation with PET (R2 = 0.56). However, 
on average, there were no statistically significant differences 
between PET and ultrasound measurements (15). Few years 
later, Stegger and colleagues were able to show a good correlation 
between PET- and MR-based measurement of LVEF in control 
and infarcted C567BL/6 mice injected with about 10 MBq of 18F-
FDG (R2 = 0.75, LVEF, mixed population) (16). However, end-
systolic and end-diastolic volumes were slightly overestimated by 
the PET technique (16).
An interesting comparison between 18F-FDG and 13N-NH3 
in healthy and infarcted male Wistar rats was later performed 
by Szymanski and colleagues showing a constant overestimation 
of ventricular volumes with 13N-NH3, which led to a significant 
underestimation of ejection fraction in rats with myocardial 
infarction (17).
Table  1 summarizes the functional parameters obtained in 
the aforementioned SPECT and PET seminal studies (9–12, 
15–17).
MeasUreMent oF CardiaC 
perFUsion
speCt
Radionuclide SPECT perfusion imaging of small animals 
relies mostly on the widely available technetium-labeled trac-
ers, although imaging of ischemic and hypertensive rats with 
201Tl-choride has also been described (18–20). One study sug-
gested that image quality is superior with 99mTc-sestamibi than 
with 99mTc-tetrofosmin (21).
The feasibility of measuring the ischemic heart size with 99mTc-
sestamibi was tested in male Sprague-Dawley and Wistar rats by 
using clinical SPECT cameras, either stationary or rotating, equipped 
with pinhole collimators (22–24). Correlation coefficients between 
histology-proved and SPECT-derived infarct sizes were excellent 
(R2 ranging from 0.89 to 0.98), whereas defect sizes, thresholds to 
define a significant uptake defect on SPECT images (range: 24–70% 
of the normally perfused segments), and injected activities (range: 
37–555 MBq) were different between studies (22–24).
A perfusion database of healthy male Sprague-Dawley rats 
imaged with 99mTc-tetrofosmin was created in the aforementioned 
paper of Strydhorst and colleagues (10).
Intersubject reproducibility of perfusion SPECT was good 
for healthy rats and slightly poorer for infarcted animals. 
Interestingly, these authors reported an unexpected relatively low 
perfusion in the distal segments of the lateral wall (10). There is 
no mention to such feature in a later study on the optimization 
of injected activity and reconstruction parameters in male Wistar 
rats imaged with 99mTc-tetrofosmin using cadmium–zinc telluride 
detectors (25).
Images of myocardial perfusion of good quality have also been 
obtained in mice. Wu and colleagues compared 99mTc-sestamibi 
SPECT images obtained by means of a pinhole-equipped clinical 
camera with 99mTc-sestamibi autoradiography in female BALB/c 
mice (26). A fair correlation between the two techniques was 
obtained (R2 = 0.72), with SPECT imaging missing some small 
infarcts close to the apex (26). A better correlation between 99mTc-
sestamibi SPECT and histological gold standard (R2 = 0.87) was 
found in another study using a triple-headed clinical camera 
equipped with single pinhole collimators on C57BL/6 male mice 
(27). The same amount of radioactivity was injected in these two 
latter studies (i.e., 370 MBq), which differed regarding the uptake 
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thresholds for the definition of segmental defects, namely, 50 and 
60% below the uptake of control groups, respectively (26, 27). 
A pool of normal CD1 female mice was also studied with 99mTc-
tetrofosmin on a dedicated small-animal SPECT, confirming a 
relatively lower uptake in the apex (11).
pet
The main advantage of PET imaging is that it allows quan-
tifying myocardial blood flow (MBF). PET radionuclide 
studies of cardiac perfusion are preferentially accomplished 
with tracers that are extracted from the blood pool with 
the highest efficiency, such as 15O-water or 13N-NH3 (28). 
Radiolabeled acetic acid (11C-acetate) has also been used as a 
perfusion tracer as it allows measuring the myocardial oxygen 
consumption (29).
Despite the most recent technological advancements and the 
superior quantitative ability of PET with respect to SPECT, a 
true kinetic modeling and quantification of MBF still represent 
a challenge in rodents because of small cardiac size, activity 
spillover, and motion artifacts, which produce a significant 
partial volume effect. The impracticability of repeated blood 
sampling is an additional obstacle, especially in mice, and 
image-derived input functions from heart ventricles suffer 
from significant errors, exceeding 100% in rats and 400% in 
mice (30, 31). Therefore, alternative models for input function 
quantification have been proposed (30). By contrast, quantifica-
tion errors due to self-absorption (attenuation) of radioactivity 
are less relevant, and attenuation correction is rarely taken 
into account in small-animal imaging studies. However, recent 
literature has suggested that photon attenuation should be cor-
rected for especially in studies in which animals of different 
body weights are compared (32). Moreover, as will be detailed 
below, the type of anesthesia can significantly influence the 
quantification of MBF.
A number of studies have shown the feasibility and repeatabil-
ity of PET measurements of MBF in non-ischemic rats. Reported 
MBF varies between 3 and 6 mL/min/g, is age related, and com-
pares well with reference measurements obtained by radioactive 
microspheres or MR (29, 33–35). As it will become clear later 
in this review, these measurements are largely dependent on the 
type and conditions of anesthesia.
In male Sprague-Dawley rats, Kudo and colleagues obtained 
a good linear correlation (R2 = 0.86) between the extent of 13N-
NH3 uptake defect—defined as showing <50% of the highest 
uptake—and the fraction of infarcted myocardium (33). The 
same group exploited the use of 13N-NH3 for quantifying the 
modifications of myocardial perfusion in C57BL/6 mice induced 
by the negative chronotropic effect of the α-2 agonist clonidine. 
By using a ROI-based approach, a 14% reduction of 13N-NH3 
uptake was demonstrated after 50% depression of HR induced by 
clonidine. Owing to the flow-dependent myocardial tracer kinet-
ics, the 14% reduction in 13N-NH3 uptake would correspond to 
a 50% reduction of cardiac blood flow, although this was only an 
indirect estimation (36).
Several fluorinated PET perfusion tracers, such as 
18F-flurpiridaz, with mechanism of uptake similar to that of clas-
sical SPECT tracers 99Tc-tetrofosmin and 99Tc-sestamibi, have 
been recently tested in small animals and are under evaluation at 
a clinical level. These have been recently reviewed (37). Finally, 
the first 82Rb PET image of a Sprague-Dawley rat with myocardial 
infarct has been recently released and shows that imaging with 
this tracer is feasible (38). It remains to be proven, however, 
that the high energetic 82Rb positron emission, with consequent 
longer path length in tissue, does not negatively affect image qual-
ity, especially in mice.
MeasUreMent oF CardiaC 
MetaboLisM
In normal conditions, cardiac energetic production relies primar-
ily on fatty acid metabolism (70–90%), whereas glycolysis plays a 
secondary role (10–30%). The hibernating myocardium, namely, 
a portion of viable heart that survived an acute ischemia or a 
chronic hypoperfusion, is characterized by a glycolytic switch 
together with reactivation of the fetal gene program (39). Imaging 
of the viable myocardium with 18F-FDG is a well-established 
clinical procedure used to select suitable candidates for coronary 
revascularization.
Cardiac hypertrophy is also characterized by a glycolytic switch 
and attracts the attention of the researchers studying the natural 
history of the disease, potential pharmacological interventions, 
and genetic or environmental risk factors. As a consequence, 
a number of studies have used 18F-FDG in combination with 
radiolabeled fatty acid analogs in the assessment of rats with 
spontaneous or induced left ventricular hypertrophy, confirming 
the expected trend of increasing 18F-FDG uptake with progress-
ing disease (40–43).
Less clear are the modifications undergone by fatty acid 
metabolism during the course of the disease which, together 
with the complexity of the involved metabolic pathways, might 
explain the absence of a widespread and standardized clinical 
use of radiolabeled fatty acid analogs in this and other cardiac 
conditions (44).
18F-FDG PET has very favorable physical properties and broad 
availability, appearing as a simple and robust imaging modality to 
assess a number of pathological conditions and their functional 
and metabolic consequences. Thus, due to prominent cardiac 
uptake in basal conditions, triggered by uncontrolled dietary 
status and external factors such as the use of anesthetics, 18F-FDG 
is frequently used to assess cardiac perfusion after an ischemic 
insult in rodent models.
In outbred wild-type mice, Stegger and colleagues found an 
excellent linear correlation (R2 = 0.96) between 18F-FDG uptake 
defects (i.e., <50% of the highest myocardial uptake) and the 
histological gold standard after permanent coronary ligation 
(45). Similar results were later confirmed by Higuchi and col-
leagues in Wistar rats (46). However, because of the unmet need 
of very high resolution, these analyses were limited to transmural 
infarcts.
The question remains as to whether 18F-FDG PET/CT is a 
suitable modality for quantification of non-transmural infarct in 
rodents. 18F-FDG was also tested against histology and compared 
with other imaging modalities in models of acute reperfused 
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myocardial infarct in male Sprague-Dawley rats. Two independ-
ent groups showed a mismatch between FDG uptake and that 
of perfusion probes (13N-NH3 and 99mTc-sestamibi, respectively), 
indicating the ability of FDG to detect peri-infarcted areas of 
stunned myocardium with a glycolytic switch (47, 48). McNulty 
and colleagues very elegantly showed such images of increased 
FDG uptake to correspond to “no-reflow” zones with concomi-
tant transient glycogen depletion (47).
Dietary changes significantly affect the 18F-FDG distribution 
in organs with inducible glucose transporters such as striated 
and cardiac muscle. On the other hand, tissues with constitutive, 
non-insulin-dependent glucose metabolism such as the brain do 
not change their rate of glucose consumption according to the 
dietary state.
A full analogy between glucose and 18F-FDG metabolism, 
expressed by a lumped constant (LC) equal to 1, is generally con-
sidered in cardiac human studies, even during euglycemic insulin 
infusion (49). A constant LC might not apply to ischemic hearts, 
simplified artificial systems or to different animal species (50).
The dependence of cardiac 18F-FDG uptake from blood 
glucose and insulin levels is not straightforward, as additional 
factors such as lipid pool are of significant impact. As a general 
rule, fasting reduces blood glucose and insulin levels, thereby 
increasing relative fatty acid metabolism and reducing cardiac 
18F-FDG uptake. By contrast, administration of glucose and/or 
insulin significantly increases cardiac glucose metabolism and, 
consequently, 18F-FDG uptake. Notably, the pattern of cardiac 
18F-FDG uptake under hyperglycemia might be biphasic, show-
ing a paradoxical inhibition with glucose blood levels above 
11.1 mmol/L (200 mg/dL), as elegantly demonstrated by Kubota 
and colleagues in rats (51).
Kreissl and colleagues studied the effects of fasting and insulin 
administration in C57BL/6 mice by keeping the conditions of 
anesthesia stable (i.e., isoflurane 2% in 100% oxygen) (52). As 
expected, the fasting overnight significantly reduced plasma 
glucose levels and cardiac 18F-FDG uptake. Accordingly, kinetic 
analysis showed significantly reduced 18F-FDG uptake rate 
constant (Ki) and glucose metabolic rates (MRglu) in the fasting 
conditions compared to fed animals. Insulin administration 
increased Ki in all animals; 18F-FDG uptake was increased in fast-
ing animals, whereas no significant changes of 18F-FDG uptake 
were seen in fed animals (52).
VariabLes aFFeCtinG CardiaC 
radionUCLide stUdies in rodents: 
types oF anestHesia
For obvious reasons, all imaging studies with rodents require 
general anesthesia.
Ketamine/Xylazine
The cyclohexamine ketamine, a phencyclidine derivate, is the 
most widely used veterinary anesthetic in combination with 
α-2 adrenergic agonists such as xylazine or medetomidine 
(53, 54). Preferred administration route is intraperitoneal (IP), 
although ketamine can also be administered intravenously and 
intramuscularly. Common dosage in rodents is 80–200  mg/kg 
given intraperitoneally.
Ketamine inhibits glutamatergic postsynaptic neuronal 
depolarization by non-competitive binding to the phencyclidine 
receptor in the N-methyl-d-aspartate (NMDA) channel (55), 
producing a cataleptic state along with analgesia, immobility, 
dissociation from the environment, and amnesia. It does not 
globally reduce cortical metabolism and glutamate release, and 
it is therefore categorized as dissociative anesthetic. In addition, 
ketamine has profound central sympathomimetic effects that are 
responsible for the most common side effects such as hallucina-
tions and increase of blood pressure and HR in humans. This 
central sympathetic stimulation, however, is partially masked 
by a concentration-dependent direct negative inotropic effect 
of ketamine on the myocardium, which is common to several 
mammals but controversial in rodents (56–58).
In veterinary medicine, most often ketamine is used in combi-
nation with xylazine, which confers muscle relaxation. The dose 
of xylazine is usually adjusted to achieve a ketamine/xylazine 
dose ratio of 10/0.5–1.
In rodents, the net effect of the combination ketamine/
xylazine on heart function is a significant bradycardia (>50% 
reduction of HR), enlarged end-diastolic dimension and reduced 
systolic function. This has been consistently shown by cardiac 
catheterism as well as ultrasound and MR techniques (59–61). 
Notably, these effects are time and strain dependent (62) and can 
be reversed by α-2 receptor blockers (e.g., atipamezole) (59).
The ketamine/xylazine mixture produces prominent systemic 
metabolic changes, particularly in the metabolism of glucose 
and catecholamine. As shown by Saha and colleagues in fed 
male Sprague-Dawley rats, blood glucose levels increase above 
8.8 mmol/L (160 mg/dL) as early as 20 min after administration 
of ketamine/xylazine, reaching peak levels of 16.1 ± 1.4 mmol/L 
(291.7 ± 26.6 mg/dL) 120 min postinjection (63). In this study, 
hyperglycemia (>8.8 mmol/L) was maintained during the entire 
length of the experiment (180 min). Fasting animals showed a less 
steep increase of blood glucose levels, which never rose above the 
hyperglycemic threshold and came back to initial values within 
150  min (63). A significant rise of glucose levels, secondary to 
ketamine/xylazine anesthesia and dependent on the dietary status, 
was confirmed by Lee and colleagues in C57BL/6 tumor-bearing 
mice (64). According to Fueger et al., fasting has little influence on 
hyperglycemia induced by ketamine/xylazine in severe combined 
immunodeficient (SCID) mice (65). Concomitant changes are 
observed in glucose regulatory hormones, in particular insulin 
and glucagon. Indeed, plasma insulin levels drop in a time-
dependent manner within the first 30 min after ketamine/xylazine 
administration in fed animals, and then reach a steady low level 
after a small peak increase 90  min postinjection. On the other 
hand, glucagon levels show profound increase between 60 and 
180 min after ketamine/xylazine injection (63). All these effects 
are significantly attenuated in fasted animals that have lower 
baseline hormone levels and reduced glycogen stores (63, 64).
Ketamine alone does not produce any modification on either 
glucose levels or insulin release; therefore, the variations in glu-
cose levels seem to be largely mediated by xylazine, which inhibits 
insulin release from pancreatic islet cells (66). This mechanism 
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is also strongly supported by the counter effects on glucose and 
insulin levels produced by the α-2 adrenergic antagonist yohim-
bine, whereas a regulatory effect of α-2 receptors on glucagon 
levels has not been univocally proven (63).
Additional modifications with variable kinetics were also 
seen in fed rats regarding adrenocorticotrophic hormone and 
corticosteroid (i.e., inhibition) as well as in growth hormone 
(i.e., increase) (63). Moreover, catecholamine plasma levels and 
peripheral activity might fluctuate due to the effects of ketamine 
and xylazine, potentially interfering with radionuclide studies 
exploring this metabolic pathway (67).
isoflurane
Isoflurane is a volatile halogenated anesthetic producing uncon-
sciousness and immobility without significant analgesia. These 
most relevant features of isoflurane are obtained by distinct inter-
actions with both central and peripheral nervous system. Similar 
to other inhaled agents of the same class, the effect on the brain 
is depression of several regions, largely mediated by sensitization 
and prolonged response of γ-aminobutyric acid type A (GABAA) 
receptors to their ligand. Additional central inhibitory effects 
are exerted on several channels including the nicotinic acetyl-
choline and serotonin receptors. Immobilization is thought to be 
obtained by increased activity of inhibitory glycine receptors and 
inhibition of NMDA and AMPA receptors (68).
Isoflurane has a very fast onset of action, and it is rapidly 
washed out after withdrawal. There is only little metabolism by 
the liver. Cardiac effects of isoflurane result from inhibition of 
potassium and calcium channels, inducing negative chronotropic 
and inotropic actions.
In a study involving 27 mice of different strains, Szczesny and 
colleagues found no significant changes in mean arterial blood 
pressure and HR during 4 h under isoflurane anesthesia vaporized 
at 1–1.3% (69). A near-linear significant drop in arterial blood 
pressure was observed above the threshold of 2% vaporization. 
These mice were kept under continuous administration of isotonic 
saline over the entire study period to maintain fluid balance (69). 
In accordance with that, additional studies found no changes in 
HR in both rats and mice under isoflurane anesthesia (61, 70). On 
the other hand, different authors found a small reduction of HR 
and cardiac index with isoflurane, through these effects are less 
prominent than observed under other types of anesthesia such as 
ketamine/xylazine and pentobarbital (59, 62).
Interestingly, variability in cardiac function between mouse 
strains in response to isoflurane appears to be not significant (62, 
69), except for a slightly higher HR depression found on BALB/c 
mice (71).
Other relevant cardiac effects of isoflurane are dose-dependent 
increased MBF (61, 70, 72, 73) and reduced infarct size after 
ischemia–reperfusion (74).
As regards glucose metabolism, in fed male Sprague-Dawley 
rats, Saha and colleagues observed a rapid blood glucose increase 
after the onset of isoflurane anesthesia, albeit less pronounced 
if compared to ketamine/xylazine (peak levels: 232.4 ± 26.3 mg/
dL, about 150 min from baseline) (63). In fasted rats, increase in 
glucose levels did not reach significance (63). Zapp and colleagues 
confirmed hyperglycemia following isoflurane in Long–Evans 
rats (75). Fueger et al. had similar results in SCID mice (65). On 
the contrary, Dandekar et al. and Loepke et al. showed decreased 
glucose levels induced by isoflurane in melanoma-bearing nude 
mice and C57BL/6 pups, respectively (76, 77). Such different 
profile of glucose levels remains unexplained, though it might be 
attributable to differences in animal handling or mice strains.
The most severe adverse effect of isoflurane is depression of 
respiratory rate, superior to that induced by ketamine/xylazine 
and pentobarbital; however, tidal volume seems to be better 
maintained during isoflurane anesthesia, accounting for relatively 
higher peripheral capillary oxygen saturation (SPO2) compared 
with pentobarbital (78).
pentobarbital
Pentobarbital belongs to barbiturates, a class of GABA mimetic 
anesthetics, which elicit their action interacting with different 
GABAA receptor subunits from those targeted by volatile anes-
thetics (79).
Barbiturates are not the anesthetic of first choice in small-animal 
research because of the lack of significant analgesic effects and of 
the narrow safety margin. However, the relative inexpensiveness, 
rapid onset of unconsciousness and easy of IP injection make 
them a valuable option. The metabolism of barbiturates occurs 
mainly in the liver; pentobarbital is metabolized primarily by the 
hepatic cytochrome P450. Large variability in pharmacokinetic 
and pharmacologic effect is observed between species, strains, 
and single individuals. Recommended dosage of pentobarbital 
varies between 40 and 60 mg/kg given intraperitoneally (53).
Although the wide range of dosages makes comparisons 
between studies difficult, observed depressive effects on cardiac 
function in rodents were generally less severe with pentobarbital 
than with ketamine/xylazine (59, 80). Interestingly, no significant 
effects on blood glucose levels have been observed (63); however, 
some authors found a twofold increase of insulin levels in 
C567BL/6 tumor-bearing mice injected with 50 mg/kg pentobar-
bital after 4 h of fasting (64). Such effect was not observed after 
20  h of fasting, suggesting that it might be related to transient 
fluctuations of glucose levels (64). Respiratory depression with 
reduction of SPO2 is of most concern after administration of 
pentobarbital (78).
iMpaCt oF anestHesia on CardiaC 
radionUCLide iMaGinG in rodents
The choice of anesthetic has profound effects on cardiac radio-
nuclide imaging in rodents. Thackeray and colleagues showed no 
impact of fasting on blood glucose levels and cardiac 18F-FDG 
uptake in C57BL/6 mice, while differences in cardiac 18F-FDG 
distribution between study groups were largely attributable to 
changes in the anesthetic protocol (81). In particular, cardiac 18F-
FDG uptake was markedly higher under continuous isoflurane 
anesthesia than after ketamine/xylazine (30.2 ± 7.9 vs 2.4 ± 2.2% 
ID/kg, respectively) (81). These authors also found that further 
reduction of cardiac uptake could be obtained by limiting the 
isoflurane anesthetic time to the length of the acquisition, by 
extending fasting duration to 18  h and by giving heparin pre-
treatment (500 U/kg intravenously) 15 min prior to 18F-FDG (81). 
FiGUre 1 | influence of anesthetic drug on cardiac 18F-FdG uptake. Coronal PET/CT (micro-SPECT/PET/CT Albira, Bruker) slices of two age- and 
weight-matched C57BL/6 male mice acquired under ketamine (50 mg/kg)/medetomidine (1 mg/kg) (a) and isoflurane (2%, 1 L/min air) (b), 60 min after 
intraperitoneal injection of 15 MBq 18F-FDG, respectively. Higher FDG uptake is clearly seen in panel (b). Both animals were awake and warmed on a heating pad 
during the uptake phase.
FiGUre 2 | influence of length of anesthesia on cardiac uptake. Coronal PET/CT (microSPECT/PET/CT Albira, Bruker) slices of two age- and weight-matched 
Balb/c male mice acquired 60 min after intraperitoneal injection of 15 MBq 18F-FDG. Both animals were warmed with a heating pad during the uptake phase; 
however, mouse (a) was kept under isoflurane anesthesia (2%, 1 L/min air) during the entire procedure, while mouse (b) was anesthetized only during the 
acquisition. Cardiac uptake is higher in mouse (a) than in mouse (b), in keeping with the longer exposition to isoflurane.
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Several independent research groups confirmed predominant 
effects of anesthesia on cardiac 18F-FDG uptake, indicating 
significantly higher values under isoflurane anesthesia than with 
ketamine/xylazine or other anesthetic agents (64, 65, 82–84). 
Besides changes in glucose metabolism, an additional possible 
explanation for reduced cardiac 18F-FDG uptake under ketamine/
xylazine or pentobarbital would be the depressive effects of these 
agents on cardiac contractility and HR which, in contrast, are not 
significantly modified under isoflurane anesthesia.
As previously described, an additional relevant effect of 
anesthesia is the increased myocardial perfusion induced by 
isoflurane, which might significantly influence the quantification 
of MBF (29). Effects of different anesthetic drugs and different 
duration of anesthesia are shown in Figures 1 and 2, respectively.
otHer VariabLes aFFeCtinG CardiaC 
radionUCLide stUdies
route of injection
Several routes of injections are possible in small-animal imaging; 
these of course have an impact on imaging results. Intravenous 
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(IV) is the standard route of injection; however, it suffers from 
unpredictable errors due to difficulties in venous cannulation 
and venous fragility, leading to tracer extravasations, especially 
in mice. A subjective qualitative evaluation might suffice for 
determining the goodness of the injection, although quantita-
tive corrections should be applied when quantification of tracer 
uptake is mandated (85, 86). Attention must be paid to avoid 
bubbles and to not inject excessive volumes—with differences 
among sex, age, and strains—usually not larger than 5  mL/kg 
in mice. An additional issue might be the speed of injection for 
tracers with potential systemic effects, such as carrier added 
meta-iodo-benzyl-guanidine.
Other suitable routes of injection are IP and retroorbital (RO). 
In an ad hoc comparative study, IV and RO proved to be nearly 
identical in terms of pharmacokinetics and extent of organ 18F-FDG 
uptake (87). As expected, IP injections showed slower kinetics with 
residual abdominal radioactivity in some cases (87). The chance of 
erroneous intra-intestinal administration must be also taken into 
account in a non-negligible percentage of cases (10–25%) (88). 
As confirmed by several groups, the differences in biodistribution 
between IP- and IV-injected 18F-FDG usually vanish at later time 
points, namely 60 min. Therefore, IP route seems to be a practical 
and robust alternative to IV in case of cardiac radionuclide studies 
using 18F-FDG (65, 87, 89, 90). It is stressed, however, that the con-
centration of the injected radionuclide should be kept consistently 
the same throughout the study, as more concentrated compounds 
might be retained in the abdominal cavity thereby reducing the 
availability in the bloodstream (90). Moreover, IP injections 
should be validated against IV on a single agent basis, as different 
molecular structures might be absorbed differently.
Interestingly, the equivalence between IP and IV injections 
does not apparently hold true for SPECT perfusion tracers such as 
99mTc-sestamibi and 99mTc-tetrofosmin. In the study by Vrachimis 
et al., image quality was much lower with IP than with IV injec-
tion for both tracers (21). Moreover, 99mTc-tetrofosmin was 
comparable to 99mTc-Sestamibi if injected RO, but not if injected 
IV. Best image quality for RO injections was found earlier (30 min 
postinjection) with 99mTc-tetrofosmin than with 99mTc-sestamibi 
(48 min postinjection) (21).
animal Handling
A correct animal handling is of paramount importance for the 
quality of small-animal imaging. Animal body temperature may 
decrease by several degrees with anesthesia; therefore, it needs 
to be strictly monitored during the experiments (78). In fact, 
non-warmed animals show a high uptake by brown fat, skeletal 
muscle and Harderian glands, which might interfere with the 
quality of images and their reproducibility. Constant warming 
during anesthesia, significantly reduce such abnormal uptakes 
(65) (see Figure 3).
ConCLUsion
State-of-the-art small-animal radionuclide imaging techniques 
allow the study of several cardiac features in rats and smaller 
rodents. However, some computational limitations exist espe-
cially in mice, due to animal weaknesses, small heart dimen-
sions, and fast movement. Besides that, a number of variables, 
not encountered in human studies and influencing imaging 
results, should be taken into account and controlled, in order 
to ensure consistency and reproducibility of data. Among these, 
the conditions of anesthesia are of upmost importance either 
because of their direct effects on cardiac function or due to 
their systemic effects, interfering with whole-body and cardiac 
metabolism.
aniMaL Care
All animal experiments were performed according to the prin-
ciples of laboratory animal care and national ethical guidelines. 
The animal experiments have been subjected to authorization 
and control by the official Canton and Swiss veterinary service 
on surveillance of animal experiments.
FiGUre 3 | influence of warming on whole-body and cardiac 18F-FdG uptake. Sagittal PET/CT (micro-SPECT/PET/CT Albira, Bruker) slices of two age- and 
weight-matched Balb/c male mice acquired under isoflurane (2%, 1 L/min air), 60 min after intravenous injection of 15 MBq 18F-FDG. Both mice were awake during 
the uptake phase but warming conditions were different: mouse (a) was not warmed, whereas mouse (b) was kept on a heating pad. Increased muscular and 
brown fat uptake as well as decreased cardiac activity is seen in (a), while panel (b) shows low background and enhanced cardiac uptake.
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